Perspectives for the Use of Bispecific Antibodies in the Third- and Subsequent-Line Therapies of Follicular Lymphoma (Resolution of Expert Panel). Clinical Oncohematology. 2024;16(2):227-228. doi:10.21320/6nkr3a68